< Terug naar vorige pagina


Safety of Medications During Pregnancy and Breastfeeding: infants of drug-addicted mothers

Boekbijdrage - Hoofdstuk

Summary Any decision on maternal pharmacotherapy should be balanced, comparing maternal and fetal/neonatal outcome to withholding any treatment. This is because there is a relevant body of evidence that uncontrolled maternal conditions also affect fetal outcome. The same holds true for breastfeeding. Drugs are not thoroughly evaluated for use during pregnancy or breastfeeding. Knowledge on safety of drugs exposure during fetal and neonatal (breastfeeding) life is limited. Pregnancy category classifications for drugs are currently used, but have their limitations. Pregnancy exposure registries to build knowledge have been implemented in the recently revised version of the FDA labelling guidelines (Pregnancy and Lactation Labeling Final Rule). Suggestive indicators of ‘likely safe during breastfeeding’ are (i) drugs commonly administered to infants, (ii) drugs that are not absorbed following oral administration, (iii) not excreted into human milk, and finally (iv) drug considered safe during pregnancy, since fetal exposure is generally longer and more extensive. Aspects of opioids, benzodiazepines, and anti-epileptics use during fetal life or via breastfeeding have been discussed to illustrate the concepts of pregnancy related clinical pharmacology, followed by a focused discussion on neonatal abstinence syndromes. We hereby aim to provide the practicing clinician with some guidance and sources of information.
Boek: Neonatology: a practical approach to neonatal diseases
Pagina's: 677 - 691
Aantal pagina's: 14
Jaar van publicatie:2018